<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00739206</url>
  </required_header>
  <id_info>
    <org_study_id>ACT10004</org_study_id>
    <nct_id>NCT00739206</nct_id>
  </id_info>
  <brief_title>Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.</brief_title>
  <official_title>A Multicenter, Open Label, Efficacy and Safety Study of Parenteral SAR97276A in the Treatment of Symptomatic Uncomplicated and Severe Malaria in Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the efficacy and safety of SAR97276A in severe
      malaria in pediatric patients. Before treating pediatric patients with severe malaria, the
      efficacy and safety of SAR97276A will be first tested in adult patients, then in pediatric
      patients, with uncomplicated malaria.

      The safety and the concentration of SAR97276A in blood and plasma will be assessed in adult
      and pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment will be administered by intramuscular or intravenous route depending on the
      cohort. The treatment will be administered as single dose or 3-day repeated dose. The
      patients will be hospitalized for 3 days and followed up to 28 days following study
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    In accordance with protocol's predefined criteria and Data Monitoring Committee recommendation
    due to insufficient level of efficacy
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination of fever clearance, general condition improvement at 48h parasite reduction at 72h and no need for rescue therapy at 72h</measure>
    <time_frame>3 initial days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parasite reduction</measure>
    <time_frame>3 initial days (72h)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>28 days post 1st study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients with uncomplicated malaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric patients with uncomplicated malaria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric patients with severe malaria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR97276A</intervention_name>
    <description>Dose based on body weight</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with uncomplicated malaria will be enrolled in cohort 1

          -  Pediatric patients with uncomplicated malaria will be enrolled in cohort 2

          -  Pediatric patients with severe malaria will be enrolled in cohort 3

          -  Plasmodium falciparum malaria confirmed in blood smear

          -  Fever within the last 24 hours.

        Exclusion Criteria:

          -  Treatment with an antimalarial agent within 72h of screening

          -  Severe concomitant disease

          -  Pregnant or breast-feeding women

          -  Women of child bearing potential not protected by an effective method of birth control

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Novo</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Libreville</city>
        <country>Gabon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Dodoma</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
    <country>Burkina Faso</country>
    <country>Gabon</country>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2008</study_first_submitted>
  <study_first_submitted_qc>August 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <last_update_submitted>June 15, 2010</last_update_submitted>
  <last_update_submitted_qc>June 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>uncomplicated</keyword>
  <keyword>severe</keyword>
  <keyword>treatment</keyword>
  <keyword>Plasmodium Falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

